Gut microbiome and human health: Exploring how the probiotic genus *Lactobacillus* modulate immune responses

Sonakshi Rastogi* and Aditi Singh

Amity Institute of Biotechnology, Amity University Uttar Pradesh, Lucknow, India

The highest density of microbes resides in human gastrointestinal tract, known as "Gut microbiome". Of note, the members of the genus *Lactobacillus* that belong to phyla Firmicutes are the most important probiotic bacteria of the gut microbiome. These gut-residing *Lactobacillus* species not only communicate with each other but also with the gut epithelial lining to balance the gut barrier integrity, mucosal barrier defence and ameliorate the host immune responses. The human body suffers from several inflammatory diseases affecting the gut, lungs, heart, bone or neural tissues. Mounting evidence supports the significant role of *Lactobacillus* spp. and their components (such as metabolites, peptidoglycans, and/or surface proteins) in modulating immune responses, primarily through exchange of immunological signals between gastrointestinal tract and distant organs. This bidirectional crosstalk which is mediated by *Lactobacillus* spp. promotes anti-inflammatory response, thereby supporting the improvement of symptoms pertaining to asthma, chronic obstructive pulmonary disease (COPD), neuroinflammatory diseases (such as multiple sclerosis, alzheimer’s disease, parkinson’s disease), cardiovascular diseases, inflammatory bowel disease (IBD) and chronic infections in patients. The metabolic disorders, obesity and diabetes are characterized by a low-grade inflammation. Genus *Lactobacillus* alleviates metabolic disorders by regulating the oxidative stress response and inflammatory pathways. Osteoporosis is also associated with bone inflammation and resorption. The *Lactobacillus* spp. and their metabolites act as powerful immune cell controllers and exhibit a regulatory role in bone resorption and formation, supporting bone health. Thus, this review demonstrated the mechanisms and summarized the evidence of the benefit of *Lactobacillus* spp. in alleviating inflammatory diseases pertaining to different organs from animal and clinical trials. The present narrative review explores in detail the complex interactions between the gut-dwelling *Lactobacillus* spp. and the immune components in distant organs to promote host’s health.

**KEYWORDS**

lactobacillus, inflammation, gut microbiome, probiotics, gut-lung axis, gutbrain axis, gut-heart axis, gut-bone axis
1 Introduction

The human body is inhabited by trillions of dynamic and diverse microbial communities that potentially regulate the physiology of the host, popularly known as the "Microbiome" (Malard et al., 2021). The human microbiome performs imperative biological functions such as immune system homeostasis, regulation of host metabolism, prevention of pathogens invasion and improvement of the epithelial barrier function (Malard et al., 2021). The highest density of microbes resides in human gastrointestinal tract, known as the "Gut microbiome" (Dwivedi et al., 2021). The predominant bacterial phyla in the gastrointestinal tract are Firmicutes and Bacteroidetes, followed by Actinobacteria and Proteobacteria (Rinninella et al., 2019). Of note, the members of the genus Lactobacillus that belong to phyla Firmicutes are the most important probiotic bacteria of the gut microbiome. These gut-residing Lactobacillus species not only communicate with each other but also with the gut epithelial lining to balance the gut barrier integrity, mucosal barrier defence and ameliorate the host immune responses (Martín et al., 2019). In addition, Lactobacillus species exhibit microbial roles by competitively excluding opportunistic pathogens from inhabiting functional niches in the gut, restraining attachment of pathogens on epithelium as well as directly killing pathogens by producing lactic acid, acetic acid, propionic acid, bacteriocins and reactive oxygen species (ROS) (Dempsey and Corr, 2022). Besides microbial roles, commensal Lactobacillus species regulate both adaptive and innate immune responses by inducing T cells, Natural Killer (NK) cells, macrophages differentiation, cytokine-production and stimulating toll-like receptors (TLRs). They also manifest immunomodulatory effect by increasing immunoglobulin-A (IgA) producing B cells expression in Peyer’s patches in the lamina propria, where they block pathogens adhesion to the intestinal epithelium (Cristofori et al., 2021). The human body suffers from several inflammatory diseases affecting the gut, lungs or neural tissues. Mounting evidence supports the significant role of Lactobacillus species in suppressing inflammatory responses by downregulating the expression of T-helper17 (Th17) inflammatory cells and their signature cytokines IL-17F, and tumor necrosis factor-alpha (TNF-α). Numerous works of literature is available that highlights the beneficial role of these commensals in ameliorating symptoms of cardiovascular-related diseases (CVD), osteoporosis, metabolic diseases such as diabetes and obesity (Zaiss et al., 2019; Archer et al., 2021; Companys et al., 2021). The genus is also reported to regulate cholesterol metabolism as well as gut-derived metabolites production such as trimethylamine-N-oxide (TMAO), short chain fatty acids (SCFAs), lipopolysaccharides (LPS), and bile acids (BA). Osteoporosis is associated with bone inflammation and resorption (Britton et al., 2014). The Lactobacillus spp. and their metabolites also act as powerful immune cell controllers and exhibit a regulatory role in bone resorption and formation, supporting bone health. (Zaiss et al., 2019).

In view of these considerations, the significant role of Lactobacillus spp. in the alleviation and treatment of human diseases presents attractive therapeutic potential. Thus, the aim of this review is to analyze the current research works implicating the potent use of these microbes and their components in mediating immune responses that affect host health. PubMed was used to search for all of the studies published over the last 15 years using the key words "lactobacillus" or "Gut microbiota" and "inflammation". More than 550 articles were found, and only those published in English and providing data on aspects related to human diseases were included in the evaluation.

2 Genus Lactobacillus as a member of the gut microbiome

Nowadays, the gut microbiome is a prominent area of scientific research as it holds imperative role in human health and pathology. Of note, the members of genus Lactobacillus are the most important probiotic bacteria. Lactobacillus spp. act by regulation of luminal pH, enhancement of barrier function by increasing mucus production, secretion of antimicrobial peptides, and by changing the gut microbial composition (Dempsey and Corr, 2022). Their cogent functional attributes include improving digestion, maintenance of gastrointestinal-barrier integrity, competition to opportunistic pathogens, neuromodulation, participation in maturation of the immune system in early life and preservation of immune homeostasis during entire life, production of metabolites, vitamins and other components (Dempsey and Corr, 2022).

Detailed taxonomic profiling reveals that the genus Lactobacillus belongs to phylum Firmicutes, class Bacilli, order Lactobacillales and family Lactobacillaceae. They are Gram-positive, catalase-negative, non-spor forming, obligate saccharolytic rods or coccobacilli with low GC (guanine and cytosine) content of the genome (Zheng et al., 2020). Members of the genus Lactobacillus are well-adapted to the hostile environment persisting in oral, gastrointestinal and vaginal tract. In healthy adult’s feces, the concentration of different lactobacilli species accounts for up to 10^8–10^9 CFU/g. Among human gut-dwelling microbial species, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus uthunensis, Ligilactobacillus ruminis, Limosilactobacillus reuteri, Lactobacillus kalixensis, Lactocaseibacillus casei, Limosilactobacillus gastricus, Limosilactobacillus antri, Lactobacillus rhamnosus, Ligilactobacillus salivarius, Limosilactobacillus fermentum, etc. are found to be permanent and form essential part (Zheng et al., 2020). Probiotic supplementation with lactobacilli species assists in altering the gut microbiota composition, thereby reducing dysbiosis and maintaining the microbial balance with a greater abundance of useful bacteria. A probiotic formulation
comprising of \textit{L. rhamnosus} GG, \textit{L. acidophilus}, \textit{L. plantarum}, \textit{L. paracasei}, and \textit{L. delbrueckii} when given orally tends to stimulate the other gut microbial species such as Prevotella and Oscillibacter that exhibited anti-inflammatory activity in rats (Zeng et al., 2021).

3 Genus \textit{Lactobacillus} and human health

As probiotics, lactobacilli play significant roles through various GM-derived metabolites and possess several health ameliorating attributes common among them are alleviation of chronic diseases, immune system stimulation, pathogen protection, and nutritional physiology.

3.1 Gastrointestinal barrier integrity

When the gut barrier becomes dysfunctional, it leads to several inflammatory conditions, such as irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and obesity. Gut-dwelling \textit{Lactobacillus} spp. were found to restore gastrointestinal barrier function directly or indirectly in mice inflammation models (Martín et al., 2019). Indirect mechanisms through which they interact with the immune system involve modulating gut microbiota, regulating intestinal epithelial barrier integrity, viscoelastic mucin layer properties, antagonistic peptides/factors production and competitive exclusion of pathogens (Cristofori et al., 2021).

3.1.1 Gut epithelial barrier

The gut epithelial barrier separates the internal intestinal milieu from the luminal environment, thereby ascertaining the permeability of nutrients and other molecules, as well as exerting a protective role by arresting the entry of microbes and toxic compounds. Studies have reported that commensal \textit{Lactobacilli} spp. maintain gut barrier integrity which depends upon the multi-protein complexes such as tight junctions, gap junctions, adherens and desmosomes (Kocot et al., 2022). These complexes are primarily made up of transmembrane proteins namely, claudin, occludin, and junctional adhesion molecules which interact with adjacent cells via zonula occludens (ZO) and actin fibers. In case of chronic inflammatory diseases or enteric infections, the intestinal barrier integrity is disrupted. Studies have reported increased expression of ZO-1, occludin and claudin proteins by \textit{L. rhamnosus} CNCM-I in enterohemorrhagic \textit{E. coli} O157:H7 infected Caco-2 cell lines (Laval et al., 2015). Similarly, \textit{L. casei} DN-114 001 up-regulates ZO-1 protein expression via activation of Toll-like receptor (TLR)-2 in Caco-2 cells. The TLR-2 binding leads to Protein kinase C (PKC) activation which causes tight junction proteins translocation, thereby enhancing gut barrier function (Kocot et al., 2022).

3.1.2 Mucus production

Gut epithelium is covered by high molecular weight glycoproteins, mainly mucins which are produced by goblet cells (Wuet al., 2020). The viscoelastic mucin layer provides protection against digestive enzymes, supports food passage and prevents translocation of microbes across lamina propria, thus imparting gut homeostasis (Wu et al., 2020). Studies have reported certain \textit{Lactobacillus} strains to regulate mucin gene expression thereby changing the mucus layer attributes and indirectly affecting the gut immune responses. Of note, \textit{L. rhamnosus} CNCM I-3690 regulated Muc2 and Muc3 gene expression in mucus-producing goblet cells in mice inflammation model, thus preventing gut barrier dysfunction and inflammation (Martín et al., 2019).

3.1.3 Anti-microbial peptides/factors

The vital function of lactobacilli strains lies in their ability to prevent pathogenic growth by synergistically inhibiting enteropathogens and stimulating the host immune system. The lactobacilli that showed \textit{in vitro} antagonistic activity against periodontal and enteric pathogens are \textit{L. oris}, \textit{L. paracasei}, \textit{L. crispatus}, \textit{L. gasseri}, \textit{L. salivarius}, \textit{L. plantarum}, \textit{L. delbrueckii}, \textit{L. rhamnosus}, \textit{L. acidophilus}, and \textit{L. fermentum}, thereby improving gut homeostasis (Nędzi-GÓra et al., 2020; Dempsey and Corr, 2022). Among the known factors that contribute to the antimicrobial ability of \textit{Lactobacillus} spp. is their tendency to produce a wide range of metabolites such as organic acids, hydrogen peroxide, nitric oxide, SCFAs and bacteriocin that impede the growth of pathogens (Sulijaya et al., 2020). Organic acids, particularly lactic acid is a potent inhibiting factor as it creates acidic cytoplasmic pH as well as permeabilize the outer membrane of Gram-negative microorganisms (Sulijaya et al., 2020). For example, \textit{L. acidophilus} 4,356 inhibited the growth of \textit{H. pylori} by abundantly producing lactic acid (Modiri et al., 2021). Nitric oxide (NO) is another inhibitory microbial metabolite. Probiotic lactobacilli can effectively elevate NO synthesis or can stimulate host macrophages for NO production. For example, \textit{L. fermentum} LF1 produces NO via the NO synthase pathway via oxidation of L-arginine to L-citrulline (Dempsey and Corr, 2022). Some may even ribosomally synthesize short peptides known as bacteriocins which possess broad-spectrum inhibitory activity against foodborne pathogens and spoilage bacteria. For example, \textit{L. plantarum} LPL-1 produced 4,347 Da plantaricin LPL-1 (Wang et al., 2018) while curvacin A is from \textit{L. curvatus} (Ahsan et al., 2022). In the genome of several other lactobacilli species, genes encoding for pediocin and plantaricin are found (Ahsan et al., 2022). The hydrogen peroxide producing lactobacilli also induce growth stagnation in pathogens. \textit{L. johnsonii} UBLJ01 genome analysis revealed NADH oxidase, lactate oxidase and pyruvate oxidase genes involved in \textit{H2O2} synthesis while \textit{in vitro} test reported their strong antagonistic potential (Ahire et al., 2021). In addition to the synthesis of
inhibitory substances, *Lactobacilli* spp. can decrease the toxicity by degradation of microbial toxins, particularly by impeding toxin expression or by binding to the pathogen’s outer membrane. For example, *L. rhamnosus* JB3 reduced the infection of *H. pylori* in the gut by either forming lipid rafts or downregulating the expression of virulent genes (Do et al., 2021).

Recently, literature is available that highlights the ability of *lactobacillus* spp. in detoxifying mycotoxins that are known to cause carcinogenesis and immune-suppression in the host. Of note, *L. coryniformis* BCH-4 and *L. plantarum* MiLAB 393 produced fungicide compounds cyclo (L-Leucyl-L-Prolyl) and 3-phenylactic acid cyclo (L-Phe-L-Pro) respectively which significantly reduced the viability of aspergillus and *candida* species (Ström et al., 2002; Salman et al., 2022). Additionally, Sunmola et al., 2019 reported the anti-viral activity of *L. plantarum* species (Ström et al., 2002; Salman et al., 2022). Nuclear Factor kappa-light chain-activated B cells (NF-activated protein kinase (MAPK) signalling pathways and expression through the regulation of TLR-2 mediated mitogen gastrointestinal tract. Similarly, Kawahara et al., 2022 reported such as echovirus whose site of primary replication is in the antiviral activity of S-layer proteins from *L. crispatus* VP6 expression in human intestinal epithelial Caco-2 cells. Also, Mousavi et al., 2018 demonstrated that *L. crispatus* microcolonies formation on the cell surface tends to block the entry of herpes simplex virus-2 particles, thus help in inhibiting the primary infection step. The rotaviruses are among the ones that bring about severe recurrent diarrhea in infants while herpes infections are physiological responses to tissue injury and/or infections, elicited by pro-inflammatory cytokines produced by monocytes, B cells, T cells, dendritic cells (DC), natural killer (NK) cells, and macrophages. Substantial evidence from colitis-induced murine model studies claims the anti-inflammatory and immunomodulatory action of *Lactobacillus* spp. in gut inflammation (Cristofori et al., 2021). These effects largely depend upon cytokine production and immune cells proliferation. Pro-inflammatory cytokines, such as IL-8 play important role in the recruitment of immune cells during an inflammatory response. Notably, *L. acidophilus* can suppress IL-8 production and enhance Toll-like receptor-2 (TLR-2) expression through the regulation of TLR-2 mediated mitogen activated protein kinase (MAPK) signalling pathways and Nuclear Factor kappa-light chain-activated B cells (NF-kB) in inflammatory epithelial cells of the intestine (Li et al., 2021). Likewise, several strains of *lactobacillus* (such as *L. acidophilus CCFM137, L. fermentum CCFM381, L. plantarum CCFM634 and CCFM734) also displayed anti-inflammatory potential by upregulating the expression of TLR-2/TLR-6 heterodimer receptor which act as an inflammatory intracellular signalling network (Ren et al., 2016). Inflammatory bowel disease (IBD) is systemic disorder that significantly perturbs the intestinal epithelial layer of the gastrointestinal tract causing four pathological conditions, Crohn’s disease (CD), ulcerative colitis (UC), microscopic colitis and pouchitis. Compare et al., 2017 reported *L. casei* DG lower pro-inflammatory IL-6, IL-8, TLR-4 and IL-1a and increase IL-10 cytokine levels in the colonic mucosa of post-infectious IBD subjects. Additionally, *L. casei* and *L. bulgaricus* significantly lowered the pro-inflammatory cytokine TNF-a in colonic mucosal samples from CD patients (De Conno et al., 2022). The Treg cells are another immunological player involved in immune-modulation and tolerance. *L. casei* M2S01 displayed anti-inflammatory action in diseases, such as CD and microscopic colitis, by enhancing Treg cell activation, IL-10 levels and restoring gut microbial flora (Liu Y et al., 2021). Necrotizing enterocolitis (NEC) is another serious gastrointestinal inflammatory condition affecting particularly premature newborns. An *ex-vivo* study carried out on human intestinal cells from the ileus of NEC infants when treated with *L. rhamnosus* HN001 displayed reduced NF-kB inflammatory pathway activation through inhibition of TLR-4 (Good et al., 2014). Furthermore, commensal *lactobacillus* spp. activates mucosal immunity by increasing IgA antibodies, resulting in the immobilization and agglutination of pathogens. The dose-dependent consumption of *lactobacillus* particularly, *L. plantarum, L. acidophilus, L. casei, L. delbrueckii subsp. bulgaricus, L. rhamnosus* accrued the number of IgA-producing immune cells connected with mucosa lamina propria as well as stimulates the immunoglobulin receptors present on epithelial cells of the intestine (Chen et al., 2022).

Adhering to the host ideal tract, lactobacilli modulate another important aspect, apoptosis and cancer, both of which are associated with mucositis. For example, *L. rhamnosus* GG actively induces antiapoptoticAkt/protein kinase B and inhibits pro-apoptotic factors via p36 MAPK pathway while cell wall components of an array of lactobacilli such as lipoteichoic acid tends to stimulate NO synthase, thereby initiating a cascade of events that bring about pathogen-infected cell death (Banna et al., 2017). Important immune events include activation of macrophages through TNF-a cytokine production and NO-mediated upregulation of two surface phagocytosis receptors (FcγRIII and TLR-2). Sun et al., 2020 reported LPS-induced inflammatory response in Caco-2 cells owing to upregulation of anti-inflammatory cytokines genes (IL10, IL4, transforming growth factor-β3 (TGF–β3 and IFN-γ)and downregulation of pro-inflammatory cytokines (IL6, IL1B, IL8 and TNF-a) along with higher

3.2 Gastrointestinal inflammatory disorders

Inflammations are physiological responses to tissue injury and/or infections, elicited by pro-inflammatory cytokines produced by monocytes, B cells, T cells, dendritic cells (DC), natural killer (NK) cells, and macrophages. Substantial evidence from colitis-induced murine model studies claims the anti-inflammatory and immunomodulatory action of *Lactobacillus* spp. in gut inflammation (Cristofori et al., 2021). These effects largely depend upon cytokine production and immune cells proliferation. Pro-inflammatory cytokines, such as IL-8 play important role in the recruitment of immune cells during an inflammatory response. Notably, *L. acidophilus* can suppress IL-8 production and enhance Toll-like receptor-2 (TLR-2) expression through the regulation of TLR-2 mediated mitogen activated protein kinase (MAPK) signalling pathways and Nuclear Factor kappa-light chain-activated B cells (NF-kB) in inflammatory epithelial cells of the intestine (Li et al., 2021).
expression of TLR-2 and NOD-like receptor genes. Also, genome analysis unfolds the activation of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway in Caco-2 cells by *L. gasseri* JM1. Another *in vivo* study demonstrated induction of innate and adaptive immune responses by *L. acidophilus* NCFB 1748 and *L. paracasei* DC412 on BALB/c inbred mice and Fisher-344 inbred rats through polymorphonuclear (PMN) cell recruitment, TNF-α secretion and phagocytosis (Azad et al., 2018). Lactobacilli encode for certain motifs within their genome, such as unmethylated CpG motifs which are recognized by TLRs that are expressed particularly in B cells and macrophages (Xiao et al., 2022). The role of *Lactobacillus* spp. in modulating immune responses is illustrated in Figure 1.

In recent research, studies involving immunomodulating role of *lactobacillus* spp. in pain management and treating allergic symptoms have gained momentum. To date, few researchers have demonstrated the prowess of *Lactobacillus* spp. in relieving inflammatory pain by regulating pro-inflammatory cytokines such as TNF-α, IL-6 and IL-1β as well as expression of COX II in the host intestinal epithelium (Santoni et al., 2021). Although the exact pathway and mechanisms involved in inflammatory pain relief are yet not investigated in detail. *L. reuteri* DSM17938 displayed antinociceptive activity causing relief in children with functional abdominal pain (Jadresin et al., 2020). The probable mechanism involves the activation of submucosal immune cells that trigger sensitivity in nerve terminals and/or tight junctions. Another randomized, placebo-controlled, double-blind, multi-centric study by Martoni et al., 2020, reported improvement in abdominal pain and IBS symptoms in adult subjects after the administration of *B. lactis* UABLa-12 and *L. acidophilus* DDS-1 for over 6 weeks. Maixent et al., 2020 also reported the efficacy of the cocktail of two *L. acidophilus* strains in relieving pain in IBD patients.
3.3 Respiratory inflammatory disorders (gut-lung axis)

_Lactobacillus_ as whole bacteria or their components (such as peptidoglycans, metabolites and surface proteins) have shown to exert an immunomodulating role in treating patients with chronic respiratory disorders. The probable mechanisms by which _Lactobacillus_ modulate lung immunity and promote respiratory health is via the “Gut-Lung axis” which is bidirectional (Du et al., 2022).

In the intestinal mucosa, pattern recognition receptors (PRRs, such as NLRs or TLRs) present on immune cells recognize _Lactobacillus_ species or their components resulting in the activation of innate immune cells which tend to reach pulmonary tissues through lymphatic circulation (Stavropoulou et al., 2021; Du et al., 2022). To elucidate, oral administration of _L. paracasei_ CNCM I-1518 caused innate lymphoid group 3 cells (ILC3s) to migrate from the gut to the lungs where ILC3 provides resistance to pneumonia (Gray et al., 2017). Moreover, _L. rhamnosus_ GG and L. _murinus_ oral supplementation promotes the migration of Treg cell to the lungs, thereby augmenting pulmonary inflammation (Zhang et al., 2018; Han et al., 2021). The Treg cells not only have the potent anti-inflammatory ability but are also found to block Th2 type immune response in the host. In addition to this, _Lactobacillus_ interaction with gastric mucosa results in the secretion of cytokines by immune cells, which through circulation reach lung tissues where they alter the immune response. Kolling et al., 2018 reported oral intake of _L. rhamnosus_ CRL1505 results in higher TNF-α, IFN-β, IFN-α, and IFN-γ cytokines levels in the lungs leading to a significant reduction in respiratory inflammations. Of note, certain _lactobacillus_ strains secrete metabolites, particularly short chain fatty acids (SCFAs) such as acetate, propionate, butyrate that can regulate host pulmonary immune responses. SCFAs affect immune response in two ways; one is when unmetabolized SCFAs directly migrate to the lungs through circulation and enhance G protein-coupled receptors (GPCRs) activation or histone deacetylase inhibition (Koh et al., 2016). The other is where SCFAs migrate to bone marrow through circulation where they increase the differentiation of macrophage and dendritic progenitor cells (MDPs) and convert them into Ly6C-monoocytes, these in turn reach the lungs and differentiate into anti-inflammatory alternatively activated macrophages (AAMs). These AAMs reduce neutrophiles recruitment and stimulate Treg cells to produce anti-inflammatory cytokines (IL-10, TGF-β), thus lower lung injury and inflammation (Anand and Mande, 2018; Du et al., 2022). Animal studies have reported higher butyrate production leads to an increase in Tregs cells and IL-10 production mediated by GPR109A receptor activation as well as restoration of IL-10 in pulmonary tissues by inhibiting histone deacetylase (Vieira et al., 2019). Spacova et al., 2020 showed that _L. rhamnosus_ GR-1 significantly prevented the severity of airway inflammation and hyperactivity by modulating Th2-mediated immune responses as well as shifting gut microbiome composition in the allergic asthma model, supporting the existence of gut-lung axis. Likewise, Li et al., 2019 investigated the efficacy of six _lactobacillus_ spp. ( _L. fermentum, L. salivarius, L. rhamnosus, L. casei, L. reuteri_ and _L. gasseri_) on the gut microbiome and airway inflammation of house dust mite (HDM)-treated asthmatic mice models. Among these, strains of _L. reuteri_ displayed improved airway inflammation with reduced total HDM-IgG1, IgE and Th2-associated pro-inflammatory cytokines with a shift in gut microbial flora. To summarize, members of _Lactobacillus_ spp. or their metabolites have potent anti-inflammatory response, thereby supporting the alleviation of symptoms of asthma, respiratory tract infections and chronic obstructive pulmonary disease (COPD) in patients. The animal and clinical trials associated with _Lactobacillus_ spp. in inflammatory disorders of various organ systems are summarized in Table 1.

3.4 Neuroinflammatory and Neurodegenerative disorders (gut-brain axis)

The role of gut-resident _Lactobacillus_ species in human brain development and functions has also been reported. The mechanism involves the exchange of neural, hormonal and immunological signals between the gastrointestinal tract and the central nervous system (CNS), primarily known as the “Gut-Brainaxis”. This bidirectional communication is mediated by tryptophan precursors and microbial metabolites such as gamma-aminobutyric acid (GABA), histamine, 5-hydroxytryptamine (5-HT), glucose, LPS, branched-chain amino acid (BCAAs), bile acids, SCFAs, and catecholamines which regulate potent pathways that are implicated in neural cell function, neurogenesis, myelination, blood–brain barrier function and synaptic pruning (Suganya and Koo, 2020). Of note, human intestinal isolates, lactobacilli were able to produce GABA in the enteric nervous system (ENS). Studies also reported the modulation of the gut microbiota on supplementation with _L. rhamnosus_ JB-1 activated the expression of γ-aminobutyric acid (GABA) receptors thereby resulting in marked improvement in cognitive responses in mice via the vagus nerve (Breit et al., 2018). Several species of _Lactobacillus_ have shown marked effects as neuromodulators and neurotransmitters (such as monoamines, serotonin, and brain-derived neurotrophic factor) (Suganya and Koo, 2020). The microbial metabolite, such as SCFAs produced primarily by lactobacilli in the gut directly affect brain neurological functions through vagal, endocrine, humoral and immune pathways by either entering circulation or crossing the blood-brain barrier (BBB). SCFAs tend to activate Treg cells, endocrine cells and neuronal cells...
### TABLE 1 Animal and clinical studies of different *Lactobacillus* strains in alleviating inflammatory diseases pertaining to different organs.

| *Lactobacillus* Strain | Diseases | Experimental model | Immunological response | Clinical outcomes | References |
|------------------------|----------|--------------------|------------------------|-------------------|------------|
| **L. casei** Lbs2      | Gastrointestinal inflammatory disorders | TNBS-induced colitis in mice | Increased Treg levels | Lower gastric inflammation | Thakur et al. (2016) |
| **L. plantaum** CCFM634 | Gastrointestinal inflammatory disorders | DSS-induced colitis in mice | Stimulated TLR2/TLR6 heterodimer | Lower gastric inflammation | Ren et al. (2016) |
| **L. fermentum** CCFM381 | Gastrointestinal inflammatory disorders | DSS-induced colitis in mice | Decreased IL-10, decreases TNF-α, IFN-γ, IL-6, and IL 12 and Inhibited NF-κBp65, COX-2 | Lower in inflammatory pain | Zhou et al. (2019) |
| **L. acidophilus** CCFM137 | Gastrointestinal inflammatory disorders | DSS-induced colitis in mice | Increases IL-10, decreases TNF-α, IL-1b, IL-12 and TGF-β levels | Lower in inflammatory pain | Zhou et al. (2019) |
| **L. salivarius** CECT5716 | Gastrointestinal inflammatory disorders | Infant C57BL/6 mice or seven-week-old female BALB/c mice | Increased IL-10 levels | Improvement in survival rate and reduction in lung inflammation | Kumova et al. (2019) |
| **L. plantaum** CIRM653 | Respiratory inflammatory disorders | 6-8-week-old C57/BL6J mice | The pulmonary inflammation response is reduced | Improvement in survival rate and reduction in lung inflammation | Vareille-Delarbre et al. (2019) |
| **L. casei** CRL 431 | Respiratory inflammatory disorders | Adult 8-week-old Swiss albino mice and immune-deficient Swiss albino mice | Lung bacterial load is decreased | Lung inflammation is reduced, accelerated weight recovery | Zelaya et al. (2013) |
| **L. fermentum** CJL-112 | Respiratory inflammatory disorders | Female, specific pathogen-free (SPF) BALB/c mice | Significant up-regulation of Th1 cytokine and IgA | Improvement in pulmonary inflammation | Yeo et al. (2014) |
| **L. kunkeei** YB38 | Respiratory inflammatory disorders | Six-eight-week-old female SPF C57/BL6J mice | Increased lung Th17 and RORγ Tregs cells | Reduction in pulmonary inflammation | Bernard-Raichon et al. (2021) |
| **L. murinus** CNCM I-5314 | Respiratory inflammatory disorders | High fat and streptozotocin (HFD/STZ)-induced C57BL/6J mice | Decrease in TNF-α and IL-6, increase GLP-1 and SCFAs levels | Reduced type 2 diabetes, GM modulation | Wang et al. (2017) |
| **L. casei** CCEF4419 | Diabetes | Eighteen (HFD/STZ)-induced Sprague-Dawley (SD) rats | Decrease in IL-10, decreases TNF-α and IL-1β in liver and colon. Downregulated expression of glucose synthase kinase 3β (GSK-3β), fatty 41 acid synthase (FAS) and sterol regulatory element-binding transcription factor 1c 42 (SREBP-1c), up-regulate the expression of protein kinase B (Akt) | Reduced inflammation in colon and liver associated with diabetes, reshape GM | Yang et al. (2019) |
| **L. acidophilus** KLDS1.1003 | Diabetes | High fat and streptozotocin (HFD/STZ)-induced C57BL/6J mice | Decrease in IL-8, TNF-α and IL-1β in liver and colon. Downregulated expression of glucose synthase kinase 3β (GSK-3β), fatty 41 acid synthase (FAS) and sterol regulatory element-binding transcription factor 1c 42 (SREBP-1c), up-regulate the expression of protein kinase B (Akt) | Reduced in inflammatory and colon and liver associated with diabetes, reshape GM | Yang et al. (2019) |
| **L. casei** LG2055 | Obesity | C57BL/6 mice | Upregulation of pro-inflammatory genes, CCL2 and CCR2. Reduction | Decrease in body weight, epididymal fat tissue mass | Miyoshi et al. (2014) |

(Continued on following page)
directly in order to increase regulatory cytokines level that maintains brain functions (Silva et al., 2020). LPS induces neurodegenerative and neuroinflammatory disease through TLR stimulation, especially TLR4 in the microglial cells and astrocytes. Studies reported that LPS/TLR4 signaling on microglial cells affects the CNS, particularly by enhancing inflammatory cytokines levels in the gut or CNS of Autism spectrum disorder (ASD) patients. Liu et al., 2019 reported oral supplementation of *L. plantarum* PS128 for 1 month drastically ameliorated ASD-related symptoms as compared with the placebo group in a double-blind, randomized, placebo-controlled study.

Existing evidence supports the significant role of *Lactobacillus* species and their beneficial metabolites in alleviating neuroinflammatory and neurodegenerative disorders in experimental models or clinical settings. Multiple sclerosis (MS) is a neuroinflammatory autoimmune disease that is characterized by myelin sheath degradation and axonal

**TABLE 1 (Continued) Animal and clinical studies of different *Lactobacillus* strains in alleviating inflammatory diseases pertaining to different organs.**

| *Lactobacillus* Strain | Diseases | Experimental model | Immunological response | Clinical outcomes | References |
|------------------------|----------|---------------------|------------------------|------------------|-----------|
| *L. brevis* OPK-3       | Obesity  | Male C57BL/6 mice   | Decrease in TNF-α, IL-6, and IL-1β, serum TG levels | Decrease in body weight, epididymal fat tissue mass | Park et al. (2020) |
| *L. fermentum* MTCC:5898| Cardiovascular diseases | Male Wistar rats | Decrease in TNF-α and IL-6 | Decrease in coronary artery risk index, atherosclerotic index, hepatic lipids, lipid peroxidation, serum total cholesterol, LDL, triglycerides | Yadav et al. (2019) |
| *L. brevis* BCRC 12310 | Cardiovascular diseases | Six -week-old SH rats | Decrease in the COX-1, COX-2, iNOS, and TNF-α levels | Anti-hypertensive effect by blocking LPS-induced NO production and | Chang et al. (2016) |
| *L. fermentum* ME-3     | Cardiovascular diseases | Human subjects | Decrease in IL-6 | Decrease in serum total cholesterol, HDL, LDL, triglyceride, oxLDL, hsCRP and HbA1C levels | Kullisaar et al. (2016) |
| *L. paracasei* FZU103   | Cardiovascular diseases | HFD-fed BALB/c mice | Up-regulated NF-kB signaling pathway | Decreased atherosclerotic lesion size, oxidative stress, chronic inflammation | Fang et al. (2019) |
| *L. rhamnosus* GR-1     | Cardiovascular diseases | Eight-week-old ApoE−/− BALB/c mice | LXR/inflammatory axis of LPS-stimulated alveolar macrophages, shift in GM | Increase cholesterol metabolism, IL-1α, SAA homeostasis | Lv et al. (2021) |
| *L. paracasei* DSM13434 | Bone Health | Six-week-old C57BL/6N female mice | Decrease in TNF-α and IL-1β | Increase in OPG levels, alleviated aortic valve- induced bone loss and resorption | Ohlsson et al. (2014) |
| *L. reuteri* ATCC 6475  | Bone health | Eleven-week old male BALB/c mice | Up-regulated Wnt10b signaling, and TNF-α levels | Alleviated glucocorticoid-induced bone loss, shift in GM with reduction in *Clostridium* | Schepper et al. (2019) |
| *L. reuteri* ATCC 6475  | Bone health | Fourteen-week C57BL/6 male mice | Decrease in TNF-α levels, Wnt10b signalling suppression | Alleviated type-I diabetes-induced bone loss | Zhang et al. (2015) |
| *L. reuteri* ATCC PTA 6475 | Bone health | Twelve-weeks BALB/c mice | Decrease in Osteoclast markers (Trap5 and RANKL), increase in CD4+ T cells | Alleviated ovariectomy-induced bone loss | Britton et al., 2014 |
| *L. plantarum* C88      | Liver injury | Calf toxin (AFB1) induced 6-week old male ICR mice | Decrease in IL-6, IL-8, JNK, NF-κB signaling pathway, Decreased levels of Bax and caspase-3, caspase-8 and elevated Bcl-2 levels in liver | Reduced inflammation and apoptosis in liver tissues | Huang et al. (2019) |
| *L. plantarum* Gut-resident | Neuroinflammation | Eight-week adult C57BL/6 mice | Blocked TLR4, IL-1β, IL-6, TNF-α, and MCP1 in brain regions | Mitigating neuroinflammation | Shukla et al. (2022) |
Kwon et al., 2013 reported that oral administration of *L. casei*, *L. acidophilus*, and *L. reuteni* to experimental mice resulted in delayed MS progression by enhancing Foxp3+ and IL10 + Tregs expression and reducing the pro-inflammatory Th1/Th17 polarization in the peripheral immune system and inflammation site. Another similar research showed suppressed MS symptoms on supplementation with *L. paracasei* DSM 13434 and *L. plantarum* DSM 15312, particularly mediated by IL-10 producing CD4+CD25+Tregs on mice (Lavasani et al., 2010). In addition to this, human gut isolates *L. reuteri* NK33, *L. mucosae* NK41, *B. longum* NK46, and *B. adolescentis* NK98 have been reported to reduce stress-induced anxiety/depression in mice. The probable mechanisms involve modulation of gut microbial composition and inflammatory immune responses by blocking the NF-κB pathway and reducing LPS, corticosterone, IL-6, and TNF-α levels in serum (Jang et al., 2019). Alzheimer’s Disease (AD) is a neurodegenerative disorder wherein considerable decline in memory, activities, cognitive ability and thinking is observed in older adults (Suganya and Koo, 2020). Studies showed intake of *L. acidophilus*, *B. bifidum* and *B. longum* in rats for 12 weeks significantly augmented their spatial learning and memory, long-term potentiation (LTP), paired-pulse facilitation (PPF) ratios, and lipid profiles (Rezaei Asl et al., 2019). Further, Castelli et al., 2020 supported the neuroprotective role of *Lactobacillus* spp. in human neuroblastoma cells, by activating pTrk, P13K/Akt, p-CREB, pERK5 pathways and restoring gut microbiota. Parkinson’s disease (PD) is another common neurodegenerative disorder marked by mood deflection, cognitive disturbances, resting tremors, slowness of movement, autonomic dysfunctions, sensory and sleep alternations, involving both the central and peripheral nervous system (Suganya and Koo, 2020). Studies have supported the role of *L. acidophilus* (LA02) and *L. salivarius* (LS01) in reducing pro-inflammatory cytokines (TNF-α, IL-6, IL-17A) and reactive oxygen species (ROS) levels and increasing anti-inflammatory cytokines (IL-4, IL-10) in peripheral blood mononuclear cells (PBMCs) thereby relieving Parkinson’s disease (PD)-associated symptoms (Magistrelli et al., 2019). The intricate crosstalk between gut and distant organs is illustrated in Figure 2.
3.5 Cardiovascular diseases (gut-heart axis)

A plethora of literature is available that documented the role of gut-dwelling Lactobacillus species in alleviating cardiovascular diseases (CVD) that specifically include diseases of the heart and blood vessels such as congestive heart failure, myocardial infarction, atherosclerosis, coronary artery disease, angina, peripheral vascular disease and aneurysm (Companys et al., 2021). Hypertension and high serum cholesterol are one of the major predisposing factors for CVD. Intestinal Lactobacillus colonies exert protective effect on the heart by regulating athero-inflammatory response, cholesterol metabolism, oxidative stress response, and gut-derived functional metabolites production such as TMAO, SCFAs, LPS, and BA (Companys et al., 2021; Papadopoulos et al., 2022). Of note, researchers also support that lactobacillus interventions could significantly impart a cardioprotective role by regulating the abundance and diversity of selective gut microbial flora (Zhao et al., 2021). To exemplify, L. salivarius Ls-33 supplementation changed gut microbiota composition by escalating the Prevotella-Bacteroides–Porphyromonas group/ Firmicutes ratio in obese heart patients (Zhao et al., 2021).

In the human body, high cholesterol level in the blood is considered one of the major predisposing factors for the development of atherosclerotic plaques in the arteries. Lactobacillus in the intestine plays an important role in assimilating cholesterol and the metabolism of triglycerides and fatty acids. The proposed mechanism of action includes: 1) Bile salts degradation through the action of microbial bile salt hydrolase (BSH), making them relatively less soluble and thus reducing their reabsorption by the intestinal epithelial layer and increasing their excretion in feces as observed in L. gasseri LBRM220 (Rastogi et al., 2021) and L. mucosae SRV5 and SRV10 (Rastogi et al., 2020). 2) Microbial conversion of cholesterol to relatively soluble form coprostanol which can readily assimilate and excreted out via feces 3) Incorporation of cholesterol by the microbial membrane as observed in strain L. acidophilus ATCC 43121 4) Production of short chain fatty acids (SCFA). SCFA can directly impede hepatic cholesterol synthesis by inhibiting 3-hydroxymethyl-3-glutaryl-CoA reductase enzyme in the liver (Amiri et al., 2021). GM analysis revealed that lactobacillus supplementation in mice model, selectively promotes the SCFAs metabolizing commensals, such as Ruminococcus, Eubacterium and Roseoburia, thereby facilitating higher levels of fermented SCFAs (Amiri et al., 2021). The study also showed L. fermentum 296 when given to high-fed rat model for 4 weeks, significantly increased HDL and reduced harmful LDL owing to their increased production of SCFA (Cavalcante et al., 2019). Further, certain lactobacillus strains are directly involved in hypercholesterolemia, such as L. plantarum 06CC2 which remarkably reduced serum low-density lipoprotein (LDL), triglycerides (TC), free fatty acid levels, apolipoprotein B and increase apolipoprotein A-1 levels in HFD Balb/c mice. At the same time, this strain also targets hepatic tissues for lipid deposition by regulating the expression of enzymes involved in cholesterol metabolism (Yamasaki et al., 2020).

Apart from BAs and SCFAs, increasing evidence demonstrates that gut-derived microbial metabolites, particularly TMAO and LPS are also involved in the progression of CVD. Trimethylamine (TMA) is a metabolic product that is metabolized by gut commensals from dietary choline and t-carnitine which when absorbed reaches the liver where it is oxidized to TMAO. The high TMAO level causes inhibition of cholesterol reverse transport, pro-inflammatory changes in arterial vessel walls, induction of high cholesterol accumulation in macrophages, platelet hyper-responsiveness and arterial thrombosis (Zhao et al., 2021). Studies have shown Lactobacillus species alleviate TMAO-associated CVD risk by restraining the growth of gut microbes that produce key enzymes involved in TMA production. This was evidenced by research work carried out by Qiu et al., 2018, wherein L. plantarum ZDY04 intervention leads to significantly lowered TMAO circulating levels and TMAO-induced atherosclerosis by altering the relative microflora population of the genus Mucispirillum and the families Erysipelotrichaceae, Lachnospiraceae, and Bacteroidaceae in the animal model. L. plantarum Dad-13 supplementation in obese adults leads to a higher population of Bacteroidetes and lower Firmicutes flora in the gut (Rahayu et al., 2021). Also, L. plantarum supplementation directly reduced serum TMAO levels as well as circulating inflammatory factors of IL8, IL-12, and leptin in CVD patients. Furthermore, LPS as a bacterial outer membrane component also induces CVD by activating macrophages to secrete pro-atherosclerotic inflammatory cytokines (IL-1, TNF-α, IL-12, IL-6, IL-8) that accelerated atherosclerosis and heart failure occurrence owing to down-regulation of mitochondrial fatty acids oxidation in cardiomyocytes (Zhao et al., 2021). Also, LPS increases platelet aggregation through TLR4-mediated leukocyte cathepsin G activation causing thrombosis (Zhao et al., 2021). The L. brevis alleviated CVD onset by blocking LPS-induced inflammatory cytokine expression in the host (Chang et al., 2016). Similarly, L. paracasei FZU103 was found to modulate the LPS-induced inflammatory axis and cholesterol metabolism in mice fed with HFD. Metagenomic studies also demonstrated shift in GM, with higher abundance of Alistipes, Ruminococcus, Helicobacter and Pseudoalteromonas but lower population of Tannerella, Blautia, and Staphylococcus in gut (Lv et al., 2021). In L. plantarum LP91-fed LPS-induced mice, expression of atherosclerotic inflammatory factors, particularly TNF-α and IL-6, vascular cell adhesion molecule, E-selectin was found to be downregulated, thus showing improvement in CVD symptoms (Aparna Sudhakaran et al., 2013).
3.6 Metabolic disorders

Many recent publications have reported the beneficial role of *Lactobacillus* spp. in assuaging the onset of metabolic disturbances, such as obesity and diabetes mellitus, which are characterized by a low-grade inflammation (Archer et al., 2021).

3.6.1 Obesity

Obesity is a multifaceted metabolic disease associated with changes in adipose tissues (AT), which is a complex endocrine organ involved in energy homeostasis. Usually, AT are subsuming adipocytes, lymphocytes, macrophages, fibroblasts, endothelial cells that produce plasminogen activator inhibitor (PAI-1), adiponectin, leptin, vascular regulators angiotensin II and cytokines (Andersen et al., 2016). The onset of obesity leads to dysfunctional AT with physiological changes in vascularization, oxidative stress levels, secreted adipokines and inflammatory state of infiltrated lymphocytes (Jo et al., 2009). In obese patients, a rise in free fatty acids (FFAs) level causes activation of signalling pathways, particularly TLRs which contribute to the pro-inflammatory response by increasing the production of molecules such as TNF-α, IL-6, IL1β, leptin, resistin, and chemokines in cells from lamina propria of gut (Khan et al., 2021). In the gut, activation of TNF-α stimulates apoptosis signalling pathways, FFAs levels and downregulates the expression of GLUT-4 transporters. In the high-fed diet (HFD) mice group, infiltration of CD8+ T cells, TNF-α, IFN-γ, and CX3CRI™ macrophages in adipose tissues in response to high glucose, FFAs and apoptosis leads to inflammation. Of note, one of the driver for inflammatory alterations and loss of gut epithelial integrity in obesity includes, leakage of bacterial endotoxin LPS (Khan et al., 2021). This leads to an inadequate distribution of lymphocytes, changes in cytokines levels, gut microbiota and immune response to dietary antigens. Much research has been centred on the importance of *lactobacillus* in treating obesity by alleviating lipid accumulation, oxidative damage, inflammation, and gut dysbiosis. A recent publication reported synergistic effects of *L. curvatus* HY7601 and *L. plantarum* KY1032 in lowering excess weight and fat accumulation in the HFD mice group with reduced inflammatory biomarkers (Park et al., 2013). Choi et al., 2020, reported weight loss in HFD-fed mice when treated with *L. plantarum* LMT1-48 with fewer lipids accumulation, immune cells infiltration in AT and adipocyte size. Notably, multiple strains of lactobacillus-particularly, *L. casei* IMVY-7280, *L. paracasei* H110, *L. paracasei* CNCM I-4034, *L. rhamnosus* CGMCC1.3, *L. rhamnosus* LA68 and *L. casei* IB5041 have proved positive effects in reducing obesity symptoms, likely, reduced weight gain, lower cholesterol levels, lower adiposity and inflammation (Wiciński et al., 2020). Similarly, *L. reuteri* GMNL-263 ameliorated symptoms pertaining to obesity in HFD-fed rats by decreasing serum pro-inflammatory factors levels and remodeling white adipose tissue (WAT) energy metabolism (Chen et al., 2018). Besides, Joung et al., 2021 reported lower fat accumulation in AT in HFD-fed mice on *L. plantarum* administration, which was attributed to altered gut microbiota with reduced Firmicutes/Bacteroidetes ratio. Overall, *Lactobacillus* strains have achieved remarkable results in the treatment of obesity-related symptoms.

3.6.2 Diabetes mellitus

Diabetes mellitus, a chronic metabolic disease is characterized by a consistently high serum glycemic index. A study of the Global Burden of Disease 2015 has reported that diabetes is one of the major causes of mortality in urban populations. There has been a significant association between the inflammatory condition and metabolic disturbances among diabetic patients. The postulated mechanism includes raised levels of the pro-inflammatory cytokine, TNF-α which inactivates insulin receptor (IRS-I) by phosphorylating serine residue. While other cytokines IFN-γ, TNF-α, and IL-1β works in a synergistic manner by infiltrating the β-cells of the pancreas, subsequently inducing cellular apoptosis and damage. Thus, higher pro-inflammatory cytokines levels in muscle, liver and adipose tissues are major drivers of diabetes pathology as they inhibit insulin signalling causing insulin resistance (Tsalamandris et al., 2019; Bezirtzoglou et al., 2021). Interestingly, *L. plantarum* Y44 showed downregulation of pro-inflammatory cytokine genes in the liver, intestine and muscle tissues particularly by activating regulatory anti-inflammatory cytokine IL-10, highlighting their immunomodulatory role (Liu et al., 2020). Likewise, *L. casei* Shirota strain showed reduced pro-inflammatory cytokines IL-4, IL-6 and C-reactive protein (CRP) levels in Streptozotocin (STZ)-induced diabetic rat models (Zarfeshani et al., 2011). Archer et al. (2021) also reported *L. fermentum* MCC2759 exhibited a reduction in glucose profile and pro-inflammatory cytokines, IL-10 in the liver, MAT, muscle and intestinal tissues in STZ-induced diabetic rats. This study also proved enhanced insulin sensitivity (GLP-1, GLUT-4, adiponectin), intestinal barrier integrity (ZO-1) and TLR-4 receptor expression. In addition to this, *L. casei* is reported to reduce serum glucose contents owing to improvement in post-immune responses via suppression of IL-2 and IFN-γ production (Qu et al., 2018). Another study by Park et al. (2015) reported that the anti-hyperglycemic effect on male db/db mice on administration of *L. rhamnosus* GG (LGG) is associated with increased ER stress and suppressed macrophages, leading to increased insulin sensitivity. Also, alteration in the expression of some diabetes-associated genes plays a role. Probiotic *L. rhamnosus* NCDC17 has reported to have anti-diabetic capacity owing to its ability to upregulate mRNA expression of glucose metabolism and insulin sensitivity related genes such as GLUT4 (glucose uptake related genes), pp-1 (glycogen synthesis related genes) and PPARG (insulin sensitivity related genes) and
downregulating G6PC (gluconeogenesis related genes) (Singh et al., 2017). Further, consumption of probiotics affects the gut microbiota composition which in turn alleviates intestinal epithelium and suppresses the immune response by reducing the TLR4 signalling pathway, ultimately increasing insulin sensitivity (Li et al., 2021). Some other postulated mechanisms include enhanced glucagon-like peptide-1 (GLP-1) secretion from intestinal L-cells to inhibit postprandial hyperglycemia by elevating the level of insulin released from pancreatic beta cells and reducing glucotoxicity (Kesika et al., 2019). A study involving L. kaifranosaciens M and L. kefifi K administration was found to stimulate GLP-1 secretion with concomitant rise in glucose metabolism (Kocis et al., 2020).

3.7 Bone health (gut-bone axis)

Metabolic bone disorder, osteoporosis is characterized by poor bone tissues, deteriorated bone mass and porosity which subsequently lead to weak and brittle bones that are susceptible to fractures (Akkawi and Zmerly, 2018). Notably, Lactobacillus spp. as whole bacteria or their metabolites and/or structural components (such as SCFAs, hydrogen sulfide (H₂S), insulin-like growth factor-1 (IGF-I), LPS and peptidoglycans, etc.) act as powerful immune cells controller and exhibit regulatory role in bone resorption and formation (Zaiss et al., 2019). Thereby, confirming their role as a linker in the “Gut-Bone axis”. Factors namely, IGF-I produced predominately in hepatic cells in response to dietary intake and gut microbes directly mediate the gut-bone axis (Zaiss et al., 2019). The microbial metabolite, H₂S acts as a gasotransmitter, is produced by gut-resident Lactobacillus spp. and stimulates bone formation and postnatal skeletal development by activating Wnt signaling (Grassi et al., 2016). In osteoblasts, Wnt signaling activation mediates enhanced osteoblastogenesis and arrests osteoblast apoptosis. Moreover, SCFAs have gained tremendous attention for their capacity to diffuse bone tissues and regulate immune responses (Zaiss et al., 2019). SCFA, particularly butyrate and propionate induce the proliferation of mature Treg cells. The maturation of Tregs depends upon GPR109a and GPR43 receptors expressed on dendritic cells (DC). The Treg cells suppress the CD4+ T cells that are present on the endosteal surfaces of the bone by producing immunosuppressive cytokines IL-10 and TGF-β, resulting in improved osteoporosis and bone mass density (BMD) by directly increasing osteoblast differentiation and reducing osteoclastogenesis (Smith et al., 2013). Also, activated Treg cells are required for calciotropic parathyroid hormone-stimulated (PTH-stimulated) bone formation as it induces bone anabolism via Treg/Wnt10b/Wnt signaling pathway (Yu et al., 2018). Dietary supplementation with L. rhamnosus LGG for 4 weeks directly increased circulating and intestinal butyrate levels, confirming its capacity to diffuse from the intestine to distant organs like bone. In bone tissues, the butyrate induces Tregs and improves bone health. This study by Tyagi et al., 2018 further proved that L. rhamnosus LGG also altered gut microbial composition, with a higher Clostridia population that is known to elicit the generation of SCFAs in the gut. Thus, L. rhamnosus LGG substantially mediates the pathway linking SCFAs, Tregs, and bone formation. To date, multiple studies have utilized animal models to determine lactobacillus efficacy in reducing both primary and secondary osteoporotic bone loss. Oral intake of L. reuteri ATCC 6475 by healthy male mice for 1 month resulted in improved bone mineral content, vertebral and femoral trabecular bone density, trabecular thickness and trabecular number when compared to untreated controls. Increased bone density leads to higher levels of bone formation rate as evidenced by the osteoblast marker osteocalcin. L. reuteri ATCC 6475 acts by systemically suppressing gene expression of pro-osteoclastogenic and pro-inflammatory cytokines in both the bone marrow and the intestine (Nilsson et al., 2018). These anti-inflammatory effects, which are also observed in other species of Lactobacillus tend to directly increase the calcium transport across the intestinal barrier. Immune cell activation largely depends on calcium levels. In case of hypocalcemia, treatment of rats with yogurt-enriched with L. casei, L. reuteri and L. gasseri improved calcium absorption in a PTH-dependent manner. Likewise, L. rhamnosus (HN001) also improved calcium and magnesium retention in rat models (Collins et al., 2017). Ohlsson et al., 2014 treated mice with either a single L. paracasei strain (DSM13434) or a mixture of three strains (L. plantarum DSM 15312, DSM 1531 and L. paracasei DSM13434) in the water for 14 days resulted in increased cortical bone mineral content and decreased levels of urinary fractional excretion of calcium and resorption marker C-terminal telopeptides as compared to control. Different Lactobacillus strains act via distinct and/or overlapping pathways, such as L. helveticus was found to not only increase bone density by elevating calcium uptake, but also secrete bioactive peptides valyl-prolyl-proline (VPP) and isoleucyl-prolyl-proline (IPP) (Parvaneh et al., 2018). Further, conversion of insoluble inorganic salts into soluble forms, protection of intestinal mineral absorption sites, triggering of the modulation of calcium-binding proteins, and minimization of the interaction of minerals with phytic acids are the main actions reported by different strains of Lactobacillus that supported bone health.

4 Future prospects

An exponential advancement in sequencing processing, genome assembly and annotation technologies, has resulted in thousands of publicly available genomes of Lactobacillus spp. Access to these data has revolutionized the molecular view of probiotic bacteria, significantly accelerating the research deciphering the complexity associated with
interactions between resident microbiota and the mucosal immune system. Notably, advancements in genomic tools, particularly functional genomics, proteomics, transcriptomics, and secretomics have helped in understanding the intricate dynamic host-microbe crosstalk that extends far beyond gastrointestinal health. To exemplify, studies on the bi-directional crosstalk between the GIT and the brain (gut-brain axis) are revealing the neurochemical importance of gut homeostasis. Similarly, studies involving the GIT and the lungs crosstalk (gut-lung axis) highlight the significance of microbial metabolites in regulating host’s immune responses. In addition, Lactobacillus spp. modulate mucosal immunity through the interaction of proteinaceous microorganism-associated molecular patterns (MAMPs) with pattern recognition receptors (PRRs) on antigen-presenting cells (APCs), such as dendritic cells and macrophages. Recently, the proteomic and genomic profiles of several lactobacilli were bioinformatically screened to create a secretome database cataloging the various extracellular proteins. For example, a proteomic-based method was used to identify S-layer associated proteins (SLAPs) in L. acidophilus. After extraction, the SLAPs were identified through mass spectrometry and referenced to the secretome database. The mutational analysis of SLAPs showed immunomodulatory phenotype using in vitro bacterial-DC co-incubation assays (Huang et al., 2021). However, it is important to note that the transcriptional networks induced by each probiotic were unique to each strain studied and that they show distinct metabolic and immunogenic profiles in the host. Thus, there is a growing need for human clinical trials with experimental designs, reflecting the future progress that has been made in the field of probiotics and GIT microbiome research.

5 Conclusion

Taken together, the intestinal microbial species, particularly Lactobacilli spp., within gut are identified as potential and talented players in restoring gastrointestinal barrier function, immune stimulation and gut microbial flora. So far, we have highlighted the intricate crosstalk between gut-dwelling Lactobacilli spp., or their metabolites and the immune components in distant organs to promote host’s health. The healthy balance in the intestinal ecosystem is preserved by the circuitry of monitoring mechanisms between potentially pro-inflammatory cell [Th cells secreting IFN-y, Th17 cells that secrete interleukin IL-17, and IL-22], and anti-inflammatory Foxp3+ receptor T-cells. Certain strains of lactobacilli stimulate the anti-inflammatory fork of the adaptive immune system by controlling Treg maturation or by driving IL-10 and IL-12 production. Given the current epidemic of inflammatory disorders plaguing present society, a call is necessary for feasible, available, and safe treatments to prevent and fight against it. Even though inflammatory and metabolic disorders pathogenesis is multifactorial and highly complexed, yet recent literature suggests modulation of gut microbial flora and immune responses using probiotics as the primary therapeutic intervention. Consequently, gut microbiome modulation to preserve a stable, consistent metabolic environment may be helpful in preventing and as additional treatment in affected patients. In future, far more in-depth clinical studies will be required to substantiate the therapeutic approaches with lactobacillus in directly maintaining gut microbiota homeostasis and regulate functional metabolites (such as TMAO, SCFAs, BAs, and LPS) which further lower risks associated with immune inflammation, high lipid cholesterol and oxidative stress. From author’s viewpoint, those looking to ameliorate their overall health by improving their gastrointestinal microbial complexity might find it more beneficial to target on consuming a fermented diet (such as yoghurt, kimchi, miso, sauerkraut) rich in Lactobacillus spp. To conclude, therapy with Lactobacillus spp. still provides a potential frontier in the treatment and prevention of inflammatory diseases.

Author contributions

SR collected literature data, wrote the manuscript, drew the figure, and tabulated the table. AS reviewed the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References

Ahire, J. J., Sahoo, S., Kashikar, M. S., Heererek, A., Lakshmi, S. G., and Mademupudi, R. S. (2021). In vitro assessment of lactobacillus crispatus UBLCP61, lactobacillus gasseri UBLG63, and lactobacillus johnsonii UBLBJ1 as a potential vaginal probiotic candidate. Probiotics Antimicrob. Proteins. doi:10.1007/s12260-021-09838-9

Ahlan, A., Mazhar, B., Khan, M. K., Mustafa, M., Hammad, M., and Ali, N. M. (2022). Bacteriocin-mediated inhibition of some common pathogens by wild and mutant Lactobacillus species and in vitro amplification of bacteriocin encoding genes. ADMET DMPK 10, 75–87. doi:10.5959/admet.1053

Akkawi, I. and Zmerly, H. (2018). Osteoporosis: Current concepts. Joints 6, 122–127. doi:10.3088/j-0038-1660790

Amiri, P., Hosseini, S. A., Ghaffari, S., Tutunchi, H., Ghaffari, S., Moshekar, E., et al. (2021). Role of butyrate, a gut microbiota derived metabolite, in cardiovascular diseases: A comprehensive narrative review. Front. Pharmacol. 12, 837509. doi:10.3389/fphar.2021.837509

Anand, S. and Mande, S. S. (2018). Diet, microbiota and gut-lung connection. Front. Microbiol. 9, 2147. doi:10.3389/fmicb.2018.02147

Andernach, C., Murphy, R. E., and Fernandez, M. L. (2016). Impact of obesity and metabolic syndrome on immunity. Adv. Nutr. 7, 66–75. doi:10.3945/an.115. 010207

Aparna Sudhakaran, V., Panwar, H., Chauhan, R., Duaury, R. K., Rathore, R. K., Batish, V. K., et al. (2013). Modulation of anti-inflammatory response in lipopolysaccharide stimulated human THP-1 cell line and mouse model at gene expression level with indigenous putative probiotic lactobacilli. Genes Nutr. 8, 637–648. doi:10.1007/s12655-013-0347-5

Archer, A. C., Muthukumar, S. P., and Halami, P. M. (2021). Lactobacillus fermentum MCC2759 and MCC2760 alleviate inflammatory response in high-fat diet-fed and streptozotocin-induced diabetic rats. Front. Microbiol. 12, 837509. doi:10.3389/fmicb.2021.837509

Ashrafi, M. A. K., Sarkar, M., and Wan, D. (2018). Immunomodulatory effects of probiotics on cytokine profiles. Biomed. Res. Int. 2018, 8063647. doi:10.1155/2018/8063647

Banna, G. L., Torino, F., Marletta, F., Santagati, M., Salemi, R., Cannarozzo, E., Banna, G. L., Torino, F., Marletta, F., Santagati, M., Salemi, R., Cannarozzo, E., et al. (2017). Lactobacillus rhamnosus GG: An overview to explore the rationale of its use in cancer. Front. Pharmacol. 8, 603. doi:10.3389/fphar.2017.00603

Bernard-Raichon, L., Colom, A., Monard, S. C., Namouchi, A., Cesamto, M., Garnier, H., et al. (2021). A pulmonary lactobacillus murinus strain induces Th17 and RORγt+ regulatory T cells and reduces lung inflammation in tuberculosi. J. Immunol. 207, 1857–1860. doi:10.4049/jimmunol.2001044

Breit, S., Kupferberg, A., Rogler, G., and Hasler, G. (2018). Vagus nerve as a potential vaginal probiotic candidate. FEMS Microbiol. Lett. 375, 53–59. doi:10.1111/fiml.13549

Breit, S., Kupferberg, A., Rogler, G., and Hasler, G. (2018). Vagus nerve as a potential vaginal probiotic candidate. FEMS Microbiol. Lett. 375, 53–59. doi:10.1111/fiml.13549

Dempsey, E., and Corr, S. C. (2022). Lactobacillus spp. for gastrointestinal health: Current and future perspectives. Front. Immunol. 13, 840245. doi:10.3389/fimmu.2022.840245

Do, A. D., Chang, C.-C., Su, C.-H., and Hou, Y.-M. (2021). Lactobacillus rhamnosus R383 inhibits Helicobacter pylori infection through multiple molecular actions. Helicobacter 26, e12806. doi:10.1111/hel.12806

Dogi, C., Garcia, G., De Moreno de Llablanc, A., Greco, C., and Cavaglieri, L. (2016). Lactobacillus rhamnosus RC307 intended for feed additive: Immune-stimulating properties and ameliorating effects on TNBS-induced colitis. Benef. Microbiol. 7, 539–547. doi:10.1159/0004210147

Du, T., Lei, A., Zhang, N., and Zhu, C. (2022). The beneficial role of probiotic lactobacillus in respiratory diseases. Front. Immunol. 13, 908010. doi:10.3389/fimmu.2022.908010

Dwivedi, M., Powali, S., Rastogi, S., Singh, A., and Gupta, D. (2021). Microbial community in human gut: a therapeutic prospect and implication in health and diseases. Lett. Appl. Microbiol. 73, 553–568. doi:10.1111/lam.13549

Fang, Y., Chen, H.-Q., Zhang, X., Zhang, H., Xia, J., Ding, K., et al. (2019). Probiotic administration of lactobacillus rhamnosus GR-1 attenuates atherosclerotic plaque formation in ApoE-/- mice fed with a high-fat diet. Eur. Rev. Med. Pharmacol. Sci. 23, 3533–3541. doi:10.26355/eurrev_201904_17722

Good, M., Sodhi, C. P., Ozolek, J. A., Buck, R. H., Goehring, K. C., Thomas, D. L., et al. (2014). Lactobacillus rhamnosus HN001 decreases the severity of necrotizing enterocolitis in neonatal mice and preterm piglets. Evidence in a role for TLR9. Am. J. Physiol. Gastrointest. Liver Physiol. 306, G1021–G1032. doi:10.1152/ajpgi.00542.2013

Grassi, F., Tyagi, A. M., Calvert, J. W., Gambari, L., Walker, L. D., Yu, M., et al. (2016). Hydrogen sulfide is a novel regulator of bone formation implicated in the bone loss induced by estrogen deficiency. J. Bone Miner. Res. 31, 949–963. doi:10.1002/jbmr.2775

Gray, J., Oehrle, K., Worthen, G., Alenghat, T., Whitsett, J., and Deshmukh, H. (2017). Intestinal commensal bacteria mediate lung mucosal immunity and promote resistance of newborn mice to infection. Sci. Transl. Med. 9, eaaf4142. doi:10.1126/scitranslmed.aaf4142

Han, W., Tang, C., Baba, S., Hamada, T., Shimazu, T., and Iwakura, Y. (2021). Oblivamin-induced airway inflammation is ameliorated in dectin-1-deficient mice, in which pulmonary regulatory T cells are expanded through modification of intestinal commensal bacteria. J. Immunol. 206, 1991–2000. doi:10.4049/jimmunol.2001337

Huang, L., Zhao, Z., Duan, C., Wang, C., Zhao, Y., Yang, G., et al. (2021). Lactobacillus plantarum C88 protects against aflatoxin B1-induced liver injury in mice via inhibition of NF-κB-mediated inflammatory responses and excessive apoptosis. BMC Microbiol. 19, 170. doi:10.1186/s12866-019-1525-4

Huang, Z., Zhou, X., Stanton, C., Ross, R. P., Zhao, J., Zhang, H., et al. (2021). Comparative genomics and specific functional characteristics analysis of
A meta-analysis of randomized clinical trials. Probiotics have been shown to ameliorate chronic low-grade inflammation and fat accumulation with gut microbiota composition change in diet-induced obese mouse models. Appl. Microbiol. Biotechnol. 105, 1203–1215. doi:10.1007/s00253-011-1060-6

Kawahara, T., Shimizu, I., Tanaka, Y., Tobita, K., Tomokio, M., and Watanabe, I. (2022). Lactobacillus crispatus strain KT-11 S-layer protein inhibits rotavirus infection. Front. Microbiol. 13, 788379. doi:10.3389/fmicb.2022.788379

Kieska, P., Swarnarathu, B. S., and Chaiyatun, C. (2019). Do probiotics improve the health status of individuals with diabetes mellitus? A review on outcomes of clinical trials. Biomed. Res. Int. 2019, 155167. doi:10.1155/2019/155167

Khan, S., Luck, H., Winer, S., and Winer, D. A. (2021). Emerging concepts in intestinal immune control of obesity-related metabolic disease. Nat. Commun. 12, 2598. doi:10.1038/s41467-020-22727-7

Kocot, A. M., Jarocka-Cyrta, E., and Drabińska, N. (2022). Overview of the importance of biotics in gut barrier integrity. Int. J. Mol. Sci. 23, 2896. doi:10.3390/ijms23093289

Kocsis, T., Molnár, B., Németh, D., Hegyi, P., Szakács, Z., Bálint, A., et al. (2020). The effect of probiotic L. acidophilus on lung transcriptional unresponsiveness and loss of early inflammatory genes in adipose tissue of diet-induced obese mice. PLoS One 15, 78297. doi:10.1371/journal.pone.0230577

Kumova, O. K., Fike, A. J., Thayer, J. L., Nguyen, L. T., Mell, J. C., Pascasio, J., et al. (2019). Lung transcriptional unresponsiveness and loss of early inflammatory genes in adipose tissue of diet-induced obese mice. PLoS One 15, 783879. doi:10.1371/journal.pone.0230587

Li, H.-Y., Zhou, D.-D., Gan, R.-Y., Huang, S.-Y., Zhao, C.-N., Shang, A., et al. (2019). Lactobacillus reuteri KY1032 in diet-induced obese mice is associated with gut microbial changes and metabolic effects in obese mice fed with a high fat diet. Food Funct. 10, 5024–5039. doi:10.1039/d0fo00439a

Li, Y., Li, Y., Yu, X., Yu, L., Tian, F., Zhao, J., et al. (2021). Physiological characteristics of lactobacillus casei strains and their alleviation effects against inflammatory bowel disease. J. Microbiol. Biotechnol. 31, 92–103. doi:10.4103/jmib.jmib_03041

Li, X.-C., Chen, M., Huang, Z.-R., Guo, W.-L., Li, L.-Z., Bai, W.-D., et al. (2021). Potential mechanisms underlying the ameliorative effect of Lactobacillus paracasei FZU103 on the lipid metabolism in hyperlipidemic mice fed a high-fat diet. Food Res. Int. 159, 109596. doi:10.1016/j.foodres.2020.109596

Magistrelli, I., Amoroso, A., Magnoli, L., Graziano, T., Cantello, R., Pane, M., et al. (2019). Probiotics may have beneficial effects in Parkinson’s disease: In vitro evidence. Front. Immunol. 10, 969. doi:10.3389/fimmu.2019.00969

Maixent, J. M., Pons, O., Sennoune, S. R., and Sadrun, S. (2020). Clinical effects of Lactobacillus strains as probiotics in the treatment of irritable bowel syndrome. Results from the LAPIBSS trial: Future objectives. J. Mol. Biol. 66, 211–214. doi:10.1515/jmbo-2020-0663

Malard, F., Dore, J., Gaugler, B., and Mohyti, M. (2021). Introduction to host microbiome symbiosis in health and disease. Microbial Immunol. 14, 547–554. doi:10.1038/s41385-020-00365-4

Martin, R., Chambon, C., Mbedhi-Hajri, N., Chain, F., Derrien, M., Escrichano-Vázquez, U., et al. (2019). The potential probiotic Lactobacillus rhamnosus CNCM I-3690 strain protects the intestinal barrier by stimulating both mucus production and cytoprotective response. Scie Rep. 9, 5389. doi:10.1038/s41598-019-41738-5

Martoni, C. J., Srivastava, S., and Leyer, G. J. (2020). Lactobacillus acidophilus DDS-1 and bifidobacterium lactis UABAl-12 improve abdominal pain severity and symptomology in irritable bowel syndrome: Randomized controlled trial. Nitrates 12, 3636. doi:10.3390/nitrates12020636

Miyoshi, M., Ogawa, A., Higurashi, S., and Kadooka, Y. (2014). Anti-obesity effect of Lactobacillus casei subsp. casei 26155 accompanied by inhibition of pro-inflammatory gene expression in the visceral adipose tissue in diet-induced obese mice. Eur. J. Nutr. 53, 599–606. doi:10.1007/s00394-013-0568-9

Modiri, S., KasaKermanshahi, R., Reza Soudi, M., Dad, N., Ebadi, M., Shahbani Zahiri, H., et al. (2021). Growth optimization of lactobacillus acidophilus for production of antimicrobial peptide acidocin 4356: Scale up from shake flask to lab-scale fermenter. Iran. J. Biotechnol. 19, 26286. doi:10.34898/IJBT.2021.218725.2686

Moussavi, E., Mavukandi, M., Teimoori, A., Atefi, A., Ghafari, S., and Samarab, Zadeh. (2018). Antiviral effects of Lactobacillus crispatus against HSV-2 in mammalian cell lines. J. Chin. Med. Assoc. 81, 262–267. doi:10.1016/j.jcma.2017.07.010

NgoGi, M., Wörhleowski, M., and Görtz, R. (2020). The effect of lactobacillus salivarius SGL03 on clinical and microbiological parameters in periodontal patients. Pol. J. Microbiol. 69, 441–451. doi:10.3301/pjm.2020-047

Nilsson, A. G., Sundh, D., Badck, F., and Lorentzon, M. (2018). Lactobacillus reuteri reduces bone loss in older women with low bone mineral density: A randomized, placebo-controlled, double-blind, clinical trial. J. Intern. Med. 284, 307–317. doi:10.1111/joim.12885

Ohlsson, C., Engdahl, C., Fàk, F., Andersson, A., Windahl, S. H., Farman, H. H., et al. (2014). Probiotics protect mice from ovaryectomy-induced cortical bone loss. PLoS One 9, e92368. doi:10.1371/journal.pone.0092368

Papadopoulos, P. D., Tsigaloa, C., Valsamaki, P. N., Konstantinidis, T. G., Vosodorau, C., and Bezirtzoglou, E. (2022). The emerging role of the gut microbiome in cardiovascular disease: Current knowledge and perspectives. BioMedecines 10, 948. doi:10.3390/bio10050948

Park, D.-Y., Ahn, Y.-T., Park, S.-H., Huh, C.-S., Yoo, S.-R., Yu, R., et al. (2013). Supplementation of lactobacillus curvatus HY7001 and lactobacillus plantarum KY1032 in diet-induced obese mice is associated with gut microbial changes and reduction in obesity. PLoS One 8, e59470. doi:10.1371/journal.pone.0059470

Park, J. E., Oh, S.-H., and Cha, Y.-S. (2020). Lactobacillus brevis OPK-3 from kimchi prevents obesity and modulates the expression of adipogenic and pro-inflammatory genes in adipose tissue of diet-induced obese mice. Nitrates 12, 904. doi:10.3390/nitrates12030904

Park, K.-Y., Kim, B., and Hyun, C.-K. (2015). Lactobacillus rhamnosus GG improves glucose tolerance through alleviating ER stress and suppressing macrophage activation in db/db mice. J. Clin. Biochem. Nutr. 56, 240–246. doi:10.3161/jcbn.14-116
Parvaneh, M., Karimi, G., Jamaliuddin, R., Ng, M. H., Zuraiat, I., and Mohammad, S. I. (2018). Lactobacillus helveticus (ATCC 27558) upregulates Runx2 and BMP2 and improves bone mineral density in osteoradionecrosis-induced bone loss rats. Clin. Interv. Aging. 13, 1555-1564. doi:10.2147/CIA.S160223

Qiu, L., Tao, X., Xiong, H., Yu, J., and Wei, H. (2018). Lactobacillus plantarum ZDY04 exhibits a strain-specific property of lowering TMAO via the modulation of gut microbiota in mice. Food Funct. 9, 4299-4309. doi:10.1039/c8fo00349a

Qiu, L., Ren, J., Huang, L., Pang, B., Liu, X., Liu, X., et al. (2018). Antidiabetic effects of lactobacillus cases fermented yogurt through reshaping gut microbiota structure in type 2 diabetic rats. J. Agric. Food Chem. 66, 12696-12705. doi:10.1021/acs.jafc.8b04874

Rahayu, E. S., Mariyati, M., Putri Manurung, N. E., Hasan, P. N., Therdthai, P., Mishima, R., et al. (2021). Effect of probiotic lactobacillus plantarum Dd-13 powder consumption on the gut microbiota and intestinal health of overweight adults. World J. Gastroenterol. 27, 107-128. doi:10.3989/wjg.v27.i11.107

Rastogi, S., Mittal, V., and Singh, A. (2020). In vitro evaluation of probiotic potential and safety assessment of lactobacillus mucosae strains isolated from donkey’s lactation. Probiotics Antimicrob. Proteins 12, 1045-1056. doi:10.1007/s12602-019-09610-0

Rastogi, S., Mittal, V., and Singh, A. (2021). Selection of potential probiotic bacteria from exclusively breastfed infant faeces with antagonistic activity against multidrug-resistant ESRAPE pathogens. Probiotics Antimicrob. Proteins 13, 739-759. doi:10.1007/s12602-021-00322-z

Ren, C., Zhang, Q., de Haan, B. J., Zhang, H., Faas, M. M., and de Vos, P. (2016). Identification of TLZ2/TLZ6 binding lactic acid bacteria for supporting immune regulation. Sci. Rep. 6, 34561. doi:10.1038/srep34561

Rezaei Ad, Z., Sepehr, G., and Salami, M. (2019). Probiotic treatment improves the impaired spatial cognitive performance and restores synaptic plasticity in an animal model of Alzheimer’s disease. Behav. Brain Res. 376, 121833. doi:10.1016/j.bbr.2019.112183

Rinninella, E., Raoul, P., Cintori, M., Franceschi, F., Miggiano, G. A. D., Gasbarmini, A., et al. (2019). What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms 7, 14. doi:10.3390/microorganisms7010014

Rodríguez-Nogales, A., Algieri, F., Garrido-Mesa, J., Vezza, T., Urrilla, M. P., Chueca, N., et al. (2017). Differential intestinal anti-inflammatory effects of lactobacillus fermentum and lactobacillus salivarius in DSS mouse colitis: Impact on microRNAs expression and microbiota composition. Mol. Nutr. Food Res. 61, 1700144. doi:10.1002/mnfr.201700144

Sagheedi, V., Uggeri, F., Begoli, L., Remelino, L., Brun, P., Bernabè, G., et al. (2020). The butyrophilic potential of lactobacillus reuteri characterized using a target-specific selection process. Front. Microbiol. 11, 532. doi:10.3389/fmicb.2020.00532

Salman, M., Tarig, A., Mustafa, G., Javed, M. R., Naheed, S., and Qamar, S. A. (2022). Cyclo-(Leuc-Lys-Pro) from lactobacillus coagulans BCH-4 inhibits the proliferation of Aspergillus flavus. An in vitro to in silico approach. Arch. MicrobioL 204, 267. doi:10.1007/s00203-022-02884-z

Santoni, M., Miccini, F., and Battelli, N. (2021). Gut microbiota, immunity and pain. Immunol. Lett. 229, 44-47. doi:10.1016/j.imlet.2020.11.010

Schepper, J. D., Collins, F., Rios-Arce, N. D., Raehtz, S., Schaefer, L., Gardinier, J. D., et al. (2019). Probiotic Lactobacillus reuteri prevents post-antibiotic bone loss by reducing intestinal dysbiosis and preventing barrier disruption. J. Bone Min. Res. 34, 681-689. doi:10.1002/jbmr.3635

Shukla, P. K., Meena, A. S., and Rao, R. (2022). Prevention and mitigation of alcohol-induced neuroinflammation by Lactobacillus plantarum 06CC2 reduces hepatic cholesterol levels and modulates bile acid deconjugation in Balb/c mice fed a high-cholesterol diet. Probiotics Antimicrob. Proteins 13, s12602-018-9429-4

Wang, Y., Qin, Y., Xie, Q., Zhang, H., Hu, J., and Li, P. (2018). Purification and characterization of plantaricin LPL-1, a novel class IIa bacteriocin produced by lactobacillus plantarum LPL-1 isolated from fermented fish. Front. Microbiol. 9, 2276. doi:10.3389/fmicb.2018.02276

Wicińska, M., Gębski, J., Gołębiowski, J., and Malinowski, B. (2020). Probiotics for the treatment of overweight and obesity in humans—a review of clinical trials. Microorganisms 8, 1148. doi:10.3390/microorganisms8081148

Yadav, R., Khan, S. H., Mada, S. B., Meena, S., Kapila, R., and Kapila, S. (2019). Butyrate attenuates lung inflammation by positively modulating Th9 cells. Front. Immunol. 10, 1564. doi:10.3389/fimmu.2019.01564

Yasmina, M., Minesaki, I., Iwaki, A., Miyamoto, Y., Ogawa, K., Nishiyama, K., et al. (2020). Lactobacillus plantarum 06CC2 reduces hepatic cholesterol levels and modulates bile acid deconjugation in Balb/c mice fed a high-cholesterol diet. Front. Nutr. Sci. 8, 614-6173. doi:10.3389/fnats.2020.00199

Yan, F., Li, N., Shi, J., Li, H., Yue, Y., Jiao, W., et al. (2019). Lactobacillus acidophilus alleviates type 2 diabetes by regulating hepatic glucose, lipid metabolism and gut microbiota in mice. Food Funct. 10, 5804-5815. doi:10.1039/c9fo01062a

Frontiers in Pharmacology frontiersin.org
Yeo, J.-M., Lee, H.-J., Kim, J.-W., Lee, J.-B., Park, S.-Y., Choi, I.-S., et al. (2014). Lactobacillus fermentum CJL-112 protects mice against influenza virus infection by activating T-helper 1 and eliciting a protective immune response. *Int. Immunopharmacol.* 18, 50–54. doi:10.1016/j.intimp.2013.10.020

Yu, M., D’Amelio, P., Tyagi, A. M., Vaccaro, C., Li, J.-Y., Hsu, E., et al. (2018). Regulatory T cells are expanded by Teriparatide treatment in humans and mediate intermittent PTH-induced bone anabolism in mice. *EMBO Rep.* 19, 156–171. doi:10.15252/embr.201744421

Zaiss, M. M., Jones, R. M., Schett, G., and Pacifici, R. (2019). The gut-bone axis: How bacterial metabolites bridge the distance. *J. Clin. Invest.* 129, 3018–3028. doi:10.1172/JCI128521

Zarfeh, A., Khaza’ai, H., Mohd Ali, R., Hambali, Z., Wahle, K. W. J., and Mutalib, M. S. A. (2011). Effect of lactobacillus casei on the production of pro-inflammatory markers in streptozotocin-induced diabetic rats. *Probiotics Antimicrob. Proteins* 3, 168–174. doi:10.1007/s12602-011-9080-9

Zelaya, H., Laino, J., Haro, C., Alvarez, S., and Agüero, G. (2013). Modulation of the immuno-coagulative response in a pneumococcal infection in malnourished mice nasally treated with Lactobacillus casei. *J. Med. Microbiol.* 62, 145–154. doi:10.1099/jmm.0.045526-0

Zeng, Z., Guo, X., Zhang, J., Yuan, Q., and Chen, S. (2021). Lactobacillus paracasei modulates the gut microbiota and improves inflammation in type 2 diabetic rats. *Food Funct.* 12, 6809–6820. doi:10.1039/d1fo00515d

Zeng, Z., Yuan, Q., Yu, R., Zhang, J., Ma, H., and Chen, S. (2019). Ameliorative effects of probiotic lactobacillus paracasei NL41 on insulin sensitivity, oxidative stress, and beta-cell function in a type 2 diabetes mellitus rat model. *Mol. Nutr. Food Res.* 63, e1900457. doi:10.1002/mnfr.201900457

Zhang, J., Ma, J.-Y., Li, Q.-H., Su, H., and Sun, X. (2018). Lactobacillus rhamnosus GG induced protective effect on allergic airway inflammation is associated with gut microbiota. *Cell. Immunol.* 332, 77–84. doi:10.1016/j.cellimm.2018.08.002

Zhang, J., Motyl, K. J., Irwin, R., MacDougald, O. A., Britton, R. A., and McCabe, L. R. (2015). Loss of bone and Wnt10b expression in male type 1 diabetic mice is blocked by the probiotic lactobacillus reuteri. *Endocrinology* 156, 3169–3182. doi:10.1210/en.2015-1308

Zhao, X., Zhong, X., Liu, X., Wang, X., and Gao, X. (2021). Therapeutic and improving function of lactobacilli in the prevention and treatment of cardiovascular-related diseases: A novel perspective from gut microbiota. *Front. Nutr.* 8, 693412. doi:10.3389/fnut.2021.693412

Zheng, J., Wittouck, S., Salvetti, E., Franz, C. M. A. P., Harris, H. M. B., Mattarelli, P., et al. (2020). A taxonomic note on the genus Lactobacillus: Description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. *Int. J. Syst. Evol. Microbiol.* 70, 2782–2858. doi:10.1099/ijsem.0.004107

Zhou, X., Liu, H., Zhang, J., Mu, J., Zalan, Z., Hegyi, F., et al. (2019). Protective effect of Lactobacillus fermentum CQPC04 on dextran sulfate sodium-induced colitis in mice is associated with modulation of the nuclear factor-κBsignaling pathway. *J. Dairy Sci.* 102, 9570–9585. doi:10.3168/jds.2019-16840